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ABSTRACT
Bladder cancer (BC) is a common urologic tumor characterized by high risk of 
recurrence and mortality. Capsaicin (CPS), used as an intravesical drug for overactive 
bladder, was demonstrated to induce cell death in different cancer cells including BC 
cells.
Here we found that treatment of high-grade BC cells with high dose of CPS 
triggers autophagy. Infact, the CPS treatment alters the redox homeostasis by 
inducing production of radicals, mitochondrial depolarization, alterations of ADP/
ATP ratio and activation of AMPK pathway stimulating the autophagic process in 
BC cells. The inhibition of autophagy, by using the specific inhibitor bafilomycin A 
or Beclin 1 knock-down, enhanced the CPS-induced cell death, demonstrating that 
CPS-induced autophagy acts as a pro-survival process in BC cells. By using PCR 
arrays and FACS analysis, we found that the CPS-treated BC cells displayed typical 
mesenchymal features of the epithelial mesenchymal transition (EMT) as elongated 
shape and over-expression of vimentin, a5 and b1 integrin subunits, integrin-like 
kinase and the anti-apoptotic Bcl-2 proteins. Moreover, we demonstrated that CPS 
treatment stimulates upregulation of Dhh/Ptch2/Zeb2 members of the Hedgehog 
signaling pathway, increases CD24, VEGFA and TIMP1 and decreases CD44 and ALCAM 
mRNA expression levels. By PTCH2 knock-down we found that the Hedgehog signaling 
pathway is involved in the CPS-induced autophagy and EMT phenotype.
Finally, we also showed that the CPS-resistant EMT-positive BC cells displayed 
an increased drug-resistance to the cytotoxic effects of mitomycin C, gemcitabine and 
doxorubicine drugs commonly used in BC therapy.
INTRODUCTION
Bladder cancer (BC), characterized by high risk 
of recurrence and mortality, is among the fifth most 
common malignancies in the world. The majority of BC 
is represented by urothelial carcinoma (UC), also known 
as transitional cell carcinoma (TCC), while squamous 
and adenocarcinomas are diffused in a small percentage 
[1]. Although BC is considered to be responsive to the 
chemotherapy regiments, only few patients respond 
to single-agent therapy. For this reason, the finding 
of innovative anti-cancer combinations and new anti-
neoplastic drugs is necessary.
Capsaicin (CPS), mainly known as food additive, 
is the active alkaloid found primarily in the chili 
peppers of the plant genus Capsicum, responsible for 
the hot pungent taste of these fruits. CPS, its derivatives 
and related compounds form a chemical group called 
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capsaicinoids, known as exciting pharmacological 
agents for their ability to exert various effects on 
human body and in different diseases such as obesity, 
cardiovascular, gastrointestinal, dermatologic 
conditions and neurogenic overactive bladder [2]. In 
the last decades, several reports have demonstrated 
that CPS treatment is able to induce both pro- and 
anti-carcinogenic effects [3]. In fact, CPS inhibits 
cell proliferation and induces cell death in a TRPV1-
dependent and independent manner in many different 
malignant human cell lines [4–6], including prostate 
and BC cells [7–9]; on the contrary, CPS promotes 
the carcinogenesis of colon, gastric and skin cancers 
stimulating cell proliferation and migration [2].
Autophagy is a self-degradative cellular mechanism 
used to degrade and recycle cytoplasmic components 
to provide energy during starvation, stress conditions 
or growth factor withdrawal promoting cell survival; 
however, excessive autophagy may also trigger 
autophagic-associated cell death [10]. It has been shown 
that CPS is able to stimulate autophagy in breast cancer 
and osteosarcoma cell lines. The CPS-induced autophagy 
is evoked at the same time with cell death and involves 
the DNA repair system functioning as a pathway that 
counteracts the CPS-induced apoptosis prolonging 
cancer cell survival [11, 12]. Moreover, several reports 
demonstrated that autophagy inhibition sensitizes BC 
cells to chemotherapy, indicating that in BC, targeting 
autophagy may be an effective therapeutic strategy to 
overcome drug resistance [13].
Novel evidence suggests that drug resistance is 
acquired by BC cells that undergo epithelial mesenchymal 
transition (EMT). EMT, characterized by morphological 
and molecular changes of cancer cells with increase of 
mesenchymal-related proteins, plays a pivotal role in 
the acquisition of malignant features such as invasion, 
metastasis and chemoresistance [14, 15]. In this regard, 
CPS induces EMT in colon cancer cells by modulating the 
reactive oxygen species (ROS) production and the AKT/
mTOR pathways [16].
In BC, the tumorigenicity and EMT process are 
regulated through constitutive activation of different 
members of the Hedgehog (Hh) signaling pathway [17, 
18]. Three Hh genes have been described in mammals: 
Sonic (SHH), Indian (IHH) and Desert (DHH). The Hh 
proteins are ligands for the patched receptor (Ptch), which 
negatively regulates smoothened protein (Smo). The Ptch 
binds to the Hh proteins, resulting in Ptch internalization 
in endosomes and lifting Ptch-mediated repression. Two 
homologous Ptch receptors, Ptch1 and Ptch2, have been 
described, both of which are able to interact with the Hh 
ligands [19].
Herein, the ability of CPS to induce autophagic 
cell survival, EMT and chemoresistance by involving the 
Hedgehog pathway was investigated in BC cell lines.
RESULTS
CPS induces autophagy in BC cells
The activation of autophagy in CPS (300 μM)-
treated BC cells was evaluated by assessing the 
processing of LC3 protein by western blot analysis. To 
this purpose, 5637 and T24 cancer cells, treated or not 
with CPS for different times, were analyzed for LC3 
mobility. A significant accumulation of LC3-II proteins, 
starting at 12 h after treatment and sustained until 72 h 
was observed in both CPS-treated BC cell lines (Figure 
1A). Similar results were obtained treating BC cells with 
rapamycin used as a positive control (data not shown). In 
addition, enhanced protein expression of sequestosome 
1 (p62/SQSTM1), involved in the delivery of autophagic 
substrates and nucleation of autophagosomes was 
observed by western blot analysis in CPS-treated BC 
cells (Figure 1A). Since some autophagy inducers exert 
their effects both at p62 synthesis and degradation levels 
[20], p62 levels were also evaluated in BC cells treated 
with CPS in combination with the lysosomial inhibitor 
bafilomycin A (BAF, 25 nM). As shown in Figure 
1B, BAF increased the p62 level in CPS-treated cells 
demonstrating the ability of CPS to induce an autophagic 
flux in BC cells. Similar results were obtained for LC3-
II levels (Figure 1B). The CPS-induced autophagy was 
further confirmed by acridine orange (AO) staining and 
FACS analysis. A marked formation of acidic vesicular 
organelles (AVOs), a morphological characteristic of the 
autophagic process, was observed in CPS-treated BC 
cells respect to untreated cells (Figure 1C).
CPS induces oxidative stress that triggers 
autophagy in BC cells
The energy sensor AMPK acts as a major 
regulator of cellular ATP levels and protects cells against 
stresses. Recent evidence demonstrated that activation 
of AMPK by calcium and ROS signalling inhibits the 
mTOR complex and induces autophagy [21]. Thus, 
we evaluated the AMPK activation by measuring its 
phosphorylation status (pAMPK), reactive oxygen species 
(ROS) generation, the mitochondrial depolarization and 
ATP levels in untreated and CPS (300 μM)-treated BC 
cells. Time-course immunoblot analysis showed that 
enhancement of pAMPK was evident at 1 h, peaked at 3 
and 6 h after CPS exposure, remaining sustained at later 
time-points (Figure 2A).
ROS signals and mitochondrial alterations have 
been associated to vanilloid-mediated effects [22]. 
Thus, the involvement of ROS production during 
stress-induced autophagy was evaluated in CPS-treated 
BC cells by cytofluorimetric analysis. We found that 
CPS treatment induces ROS generation in BC cells, 
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with a sustained accumulation which begins at 8 h and 
increases at later time-points (Figure 2B). The ROS 
scavenger N acetylcysteine (NAC, 10 mM) completely 
inhibited ROS production, indicating that CPS stimulates 
peroxide accumulation in BC cells (Figure 2C). 
Moreover, to better assess the source of CPS-induced 
ROS generation, BC cells were treated with CPS alone 
or in combination with the mitochondrial respiratory 
chain inhibitor rotenone (ROT, 1 μM) or the NAD(P)H 
oxidase inhibitor diphenyleneiodonium (DPI, 0.1 μM). 
As shown in Figure 2C, ROT and DPI markedly reduced 
ROS production indicating that CPS treatment affects 
both the mitochondrial respiration and the membrane-
bound enzyme complex (Figure 2C). Since mitochondrial 
dysfunction is often associated with ROS generation, we 
used JC-1 labeling and cytofluorimeter to analyze ΔΨm in 
5637 and T24 BC cells. We found that treatment with CPS 
induces a time-dependent decrease of red fluorescence 
(depolarization). The CPS-induced ΔΨm dissipation was 
evident at 6 h, increased at 12 h and remained sustained 
at 24 h (Figure 2D). Changes in ADP/ATP ratio are 
indicative of alterations in energy metabolism. By using 
bioluminescent assay, we also demonstrated that the ADP/
ATP ratio is increased in CPS-treated as compared with 
untreated cells (Figure 2E).
The cysteine protease Atg4C, regulated by ROS 
generation, is involved in the formation and maturation 
of autophagosomes and represents the main cellular target 
of oxidative signals in CPS-induced autophagy [23]. 
Herein we found that CPS increases at 1-6 and 12-24 h 
the expression of Atg4C protein in T24 and 5637 BC cells, 
respectively (Figure 2F). Finally, by western blot analysis, 
Figure 1: The CPS treatment triggers autophagy in BC cells. A. Lysates from BC cells, untreated or treated for different times 
with CPS (300 μM) were separated on 14% or 8% SDS-PAGE and probed with anti-LC3 and anti-p62 Abs respectively. GAPDH protein 
levels were evaluated as loading control. Cropped blots are representative of one out of three separate experiments. Bars represent the 
densitometric analysis, shown as the mean ± SD of three different experiments, evaluated using untreated cells as calibrator. *p< 0.01 CPS-
treated cells vs untreated. B. Lysates from BC cells, untreated or treated for 12 h with CPS (300 μM) alone or in combination with BAF (25 
nM) were separated on 14% or 8% SDS-PAGE and probed with anti-LC3 and anti-p62 Abs respectively. GAPDH protein levels were used 
as loading control. Cropped blots are representative of one of three separate experiments. Bars represent the densitometric analysis, shown 
as the mean ± SD of three different experiments, evaluated using untreated cells as calibrator. *p< 0.01 vs untreated; #p<0.01 CPS+BAF- vs 
CPS or BAF-treated cells. C. AVOs were evaluated by AO staining and cytofluorimentric analysis in BC cells untreated or treated with CPS 
(300 μM) for 48 h. Dot plots are representative of one out of three separate experiments.
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Figure 2: CPS triggers ROS production altering the mitochondrial redox homeostasis in BC cells. A. Lysates from BC 
cells, untreated or treated for different times with CPS (300 μM) were separated on 10% SDS-PAGE and probed with anti-pAMPK mAb 
and anti-AMPK Ab. Cropped blots are representative of one of three separate experiments. Bars represent the densitometric analysis, 
shown as the mean ± SD of three different experiments, evaluated using untreated cells as calibrator. *p<0.01 CPS-treated vs untreated 
cells. B. ROS production was evaluated by DCFDA staining and cytofluorimetric analysis in 5637 and T24 cells treated for different times 
with CPS (300 μM). Data, shown as the mean ± SD of three independent experiments, are expressed as fold change with respect of ROS 
basal level. *p<0.01, CPS-treated vs untreated cells.C. ROS production was evaluated as above described in BC cells treated for 24h 
with CPS (300 μM) alone or in combination with NAC (10 mM), ROT (1 μM) or DPI (0.1 μM). Data, shown as the mean ± SD of three 
independent experiments, are expressed as fold change with respect of ROS basal level. *p<0.01 CPS-, CPS+ROT or CPS+DPI-treated vs 
untreated cells; #p<0.01 CPS+ROT or CPS+DPI-treated vs CPS-treated cells. D. Time course analysis of ΔΨm changes in 5637 and T24 
cells untreated or treated for different times with CPS (300 μM), was evaluated by JC-1 staining and biparametric FL1 (green)/FL2(red) 
flow cytometric analysis. Numbers indicate the percentage of cells showing a drop in ΔΨm-related red fluorescence intensity. Data are 
representative of one out of three separate experiments. E. ADP/ATP ratio in T24 and 5637 cells, untreated or treated with CPS (300 μM) for 
12 h, was evaluated by bioluminescent assay. Data are the mean ± SD of three independent experiments. *p<0.01 CPS-treated vs untreated 
cells. F. Lysates from BC cells, treated as described in panel A, were separated on 10% SDS-PAGE and probed with Atg4C or anti-GAPDH 
Abs. Cropped blots are representative of one of three separate experiments. Bars represent the densitometric analysis, shown as the mean 
± SD of three different experiments, evaluated using untreated cells as calibrator *p<0.01 CPS-treated vs untreated cells. G. Lysates from 
BC cells, treated for 72 h with CPS (300 μM) alone or in combination with NAC (10 mM) were separated on 14% SDS-PAGE and probed 
with anti-LC3 Ab. GAPDH protein levels were used as loading control. Bars represent the densitometric analysis, shown as the mean ± SD 
of three different experiments, evaluated using CPS-treated cells as calibrator. *p<0.01 CPS+NAC- vs CPS-treated cells.
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we demonstrated that the ROS inhibitor, NAC (10 mM) 
reverted the CPS-induced autophagy (Figure 2G). NAC 
alone did not induce changes in the LC3 levels respect 
to untreated cells (Supplementary Figure 1A). Overall, 
our data demonstrated in BC cells that CPS treatment 
alters the mitochondrial redox homeostasis and induces 
autophagy in a ROS dependent manner.
Finally to evaluate the effects of CPS on 
autophagic gene pathway, we performed a RT Profiler 
array comparing untreated with CPS-treated BC cells 
at 12 h after treatment. We found that GABARAPL1, 
MAP1LC3B, SQSTM1, IRGM, ULK1, TNF and PTEN 
genes mediating different steps of the autophagic process 
were strongly upregulated and FADD and TP73, involved 
in the apoptotic pathway and IGF1, implicated in cell 
proliferation, were downregulated (Table 1).
CPS-induced autophagy acts as pro-survival 
mechanism in BC cells
In cancer, autophagy is generally thought to play 
a pro-survival role allowing cancer cells to survive 
during metabolic stress; however excessive autophagy 
can also induce cell death [10]. To better understand 
the role of CPS-induced autophagy, we evaluated, by 
cytofuorimetric analysis, cell death/survival in BC cells 
treated for different times with CPS (300 μM) in the 
presence or not of the autophagic inhibitor BAF (25 
nM). By PI and annexin V staining, we found that CPS 
induces necrotic cell death in a time-dependent manner 
in 5637 and T24 BC cells, and that BAF enhances the 
CPS-induced cytotoxic effects (Figure 3A and 3B).
Moreover, since a pivotal role of Atg6/Beclin-1 in 
autophagy, we knocked-down Beclin 1 gene (siBeclin 
1) in BC cells. As shown in Figure 3C, Beclin 1 protein 
expression was strongly down regulated in siBeclin 1, 
compared with control-BC cells (siGLO). The siBeclin 1 
and siGLO BC cells were treated with CPS for 72 h and 
cell growth was evaluated by MTT assay. Interestingly, 
knock-down of Beclin 1, that abrogates CPS-induced 
autophagy (Figure 3D), strongly reduced BC cell 
growth (Figure 3E). Overall, these results demonstrated 
a survival role for CPS-induced autophagy in BC cells.
Table 1: CPS stimulates the autophagic signaling pathway in BC cells
Gene Bank ID Symbol Description
Fold change
5637 cell line T24 cell line
NM_003824 FADD Fas (TNFRSF6)-associated via death domain −2.01 −1.78
NM_031412 GABARAPL1 GABA(A) receptor-associated protein like 1 3.59 1.74
NM_001017963 HSP90AA1 Heat shock protein 90kDa alpha (cytosolic), class A member 1 −1.13 2.31
NM_000618 IGF1 Insulin-like growth factor 1 (somatomedin C) −12.77 −3.07
NM_001145805 IRGM Immunity-related GTPase family, M 3.28 1.13
NM_022818 MAP1LC3B Microtubule-associated protein 1 light chain 3 beta 2.20 2.69
NM_000314 PTEN Phosphatase and tensin homolog 4.10 1.13
NM_003900 SQSTM1 Sequestosome 1 2.69 1.79
NM_000594 TNF Tumor necrosis factor 7.54 8.34
NM_003565 ULK1 Unc-51-like kinase 1 (C. elegans) 2.52 1.41
NM_005427 TP73 Tumor protein p73 −1.74 −2.17
Autophagy RT profiler PCR array in mRNA samples extracted from 5637 and T24 BC cells treated for 12 h with vehicle or CPS 
(300 μM). Values represent fold differences of individual gene expression in CPS- compared to vehicle-treated BC cells. The 
expression levels were normalized to the average Ct value of two housekeeping genes (GAPDH and RPLP0) and calculated by 
the ΔΔCt method. In bold up-regulated genes. Data shown are representative of one out of three separate experiments.
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CPS-induced autophagy triggers epithelial 
mesenchymal transition (EMT) in BC cells
Since the CPS-induced autophagy acts as a pro-
survival process, BC cells were treated with CPS (300 
μM) for 72 and 120 h to assess the proliferative capability 
by MTT and BrdU incorporation. Our results evidenced 
that CPS-resistant BC cells are actively replicating (Figure 
4A and 4B), suggesting that they could be responsible for 
bladder cancer relapse.
Then, we better characterized the phenotype of CPS-
resistant BC cells at 120 h after CPS treatment by light 
microscopy and cytofluorimetric analysis. As shown in 
Figure 4C and Supplementary Figure 1B, CPS-treated BC 
cells, displayed an increased cell size and morphological 
changes with a conversion from a “cuboidal” epithelial 
structure into an elongated mesenchymal shape, compared 
to untreated cells, suggesting that prolonged exposure to 
CPS stimulates the EMT process in BC cells. To further 
address the presence of the EMT phenomenon in CPS-
resistant BC cells, we investigated the expression of 
markers typical of the epithelial mesenchymal transition. 
Our results showed that the expression of E-cadherin is 
significantly reduced in CPS-treated cells, respect to 
untreated BC cells, whereas vimentin, α5 and β1 integrin 
subunits, ILK and Bcl-2 are upregulated (Figure 4D), 
indicating the occurrence of EMT and the acquisition of 
a more aggressive phenotype in CPS-resistant BC cells.
CPS induces autophagy and EMT in an 
Hedgehog signaling pathway dependent manner
The Hedgehog pathway has been found to regulate 
autophagy and EMT [24–26]. Thus, we first evaluated by 
quantitative real time PCR (qRT-PCR) the expression of 
different members of Hedgehog signaling pathway, Shh, 
Ihh and Dhh ligands, their specific receptors, Patched 1 
and 2 (Ptch1 and Ptch2) and some related genes such as 
Zeb1, Zeb2, ALCAM and VEGFA in BC cells treated 
with CPS for 120 h. Upregulation of the Dhh/Ptch2/Zeb2 
pathway as well as downregulation of Shh or Ihh/Ptch1/
Zeb1 genes were observed in CPS-treated BC cells as 
respect to untreated cells. In addition, increased CD24, 
VEGFA and TIMP1 and decreased CD44 and ALCAM 
mRNA levels were found in both T24 and 5637 BC cell 
lines (Table 2).
Figure 3: The CPS-induced autophagy acts as a pro-survival process in BC cells. A. Cell death was evaluated in BC cells, 
untreated or treated for different times with CPS (300 μM) alone or in combination with BAF (25 nM) by FACS analysis. Data shown are 
the mean ± SD of three independent experiments. *p<0.01 vs untreated; #p<0.01 CPS plus BAF vs CPS- or BAF-treated cells. B. Cell death 
type was determined by Annexin V/PI staining and cytofluorimetric analysis in BC cells after 72 h of treatment with CPS (300 μM) alone 
or in combination with BAF (25 nM). Data are representative of one out of three separate experiments. Numbers represent the percentage 
of positive cells. C. Lysates from siGLO and siBeclin 1 BC cells were separated on 8% SDS-PAGE and probed with anti-Beclin 1 Ab. 
Cropped blots are representative of one of three separate experiments. Bars represent the densitometric analysis, shown as the mean ± SD 
of three different experiments, evaluated using siGLO cells as calibrator. *p<0.01 siBeclin 1 vs siGLO cells. D. Lysates from siGLO and 
siBeclin 1 BC cells treated for 72 h with CPS (300 μM) were separated on 14% SDS-PAGE and probed with anti-LC3 Ab. Cropped blots 
are representative of one of three separate experiments. Bars represent the densitometric analysis, shown as the mean ± SD of three different 
experiments, evaluated using siGLO cells as calibrator. *p<0.01 CPS-treated siBeclin 1 vs CPS-treated siGLO cells. E. Cell viability was 
assessed by MTT assay in siGLO and siBeclin 1 BC cells treated for 72 h with CPS (300 μM). Data shown are the mean ± SD of three 
independent experiments. *p<0.01 siBeclin 1 vs siGLO CPS-treated BC cells.
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To better investigate the role of the Hedgehog 
pathway, BC cells were silenced for PTCH2 (siPTCH2). 
A reduction of PTCH2 mRNA was observed in siPTCH2 
as respect to siGLO (control) BC cells (Figure 5A). 
Therefore, we treated silenced BC cells with CPS for 
72 and 120 h to assess autophagy and EMT transition, 
respectively. Our results showed that the LC3II/LC3I 
ratio is reduced in siPTCH2 compared with siGLO 
BC cells (Figure 5B) and more interestingly, FACS 
analysis displayed that PTCH2 knockdown decreased 
the expression of vimentin and α5 integrin subunit in 
CPS-treated cells. Overall our findings demonstrated 
that the Hedgehog signaling pathway is involved in 
CPS-induced autophagy and EMT phenotype in BC 
cells.
The EMT, induced by CPS, promotes 
chemotherapeutic drug-resistance of BC cells
Hedgehog signaling pathway activation is positively 
correlated with chemoresitance in cancer cells [24, 27]. Thus, 
we finally investigated the drug-sensitivity of CPS-induced 
EMT cells to chemotherapeutic agents commonly used 
in BC therapy. To this purpose, CPS-exposed (120 h) BC 
cells, were further treated for additional 48 h with different 
doses of mitomycin C, gemcitabine and doxorubicine. As 
shown in Figure 6A and 6B, the CPS-resistant BC cells 
were significantly less sensitive to chemotherapeutic agents 
compared with untreated cells. In fact the IC50 resulted about 
two-three fold higher for all tested drugs in CPS-treated BC 
cells respect to untreated cells.
Figure 4: The CPS-resistant BC cells display the EMT phenotype. A. Cell growth was assessed by MTT assay in 5637 and T24 
BC cells treated for 72 h or 120 h with CPS (300 μM). Data shown are the mean ± SD of three independent experiments. *p<0.01 120 h 
CPS-treated vs 72 h CPS-treated BC cells.B. Cell replication was assessed by BrdU incorporation and FACS analysis in BC cells treated for 
120 h with CPS (300 μM) and cultured in medium for additional 24 h. One representative out of three independent experiments is shown. 
Numbers indicate the Mean Fluorescence Intensity (MFI).C. Cell morphology was evaluated by light microscopy in BC cells, untreated or 
treated with CPS (300 μM) for 120 h. One representative out of three independent experiments is shown. Bar = 25 μM. D. FACS analysis 
was performed in BC cells, untreated or treated with CPS (300 μM) for 120 h, stained with anti-E cadherin, anti-vimentin, anti-β1 and 
anti-α5 integrin subunits, anti-ILK and anti-Bcl2 Abs followed by respective FITC-conjugated secondary Abs. One representative out of 
three independent experiments is shown. Numbers indicate the Mean Fluorescence Intensity (MFI).
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Taken together, our results demonstrated that 
CPS-resistant 5637 and T24 BC cells showing the EMT 
phenotype display chemotherapeutic drug-resistance.
DISCUSSION
Herein, we demonstrated that CPS, by triggering 
autophagic cell survival, stimulates BC cells to undergo 
epithelial mesenchymal transition and to develop 
chemotherapeutic drug-resistance through the Hedgehog 
signalling pathway.
In CPS-treated BC cells, cellular energy 
imbalance resulting from ROS generation, alterations 
of ATP levels, mitochondrial depolarization and AMPK 
signalling pathway activation, promotes autophagy as 
demonstrated by the enhancement of LC3-II/LC3-I ratio 
and accumulation of p62 protein evaluated in CPS plus 
BAF-treated BC cells. We also demonstrated by using the 
ROS inhibitor NAC that the intracellular ROS production, 
triggered by CPS in BC cells, is responsible for the 
oxidative stress-induced autophagy, that started at 12 h 
and remained sustained until 72 h. The time-dependent 
increase of p62 SQSTM1 protein expression was a 
consequence of enhanced transcription level as evidenced 
by qRT-PCR. Moreover, CPS treatment increased the 
expression of autophagic genes such as GABARAPL1 
and MAP1LC3B associated with autophagic vesicles 
formation [28], IRGM and ULK1 engaged in the 
autophagy complex initiation [29], TNFα and PTEN, 
involved in autophagy induction [30, 31].
Autophagy promotes stress-induced cell survival 
or autophagic cell death [10]. In this regard, we showed 
that CPS-induced autophagy mediates a pro-survival 
effect in 5637 and T24 BC cells. In fact a marked 
increase of necrotic cells was evident in BC cells treated 
with CPS in combination with the autophagic inhibitor 
BAF. In addition, knockdown of Beclin 1, that inhibits 
the CPS-induced autophagy, reduces the growth of BC 
cells. Similarly, it has been recently demonstrated that 
CPS-induced autophagy rescues breast carcinoma and 
osteosarcoma cells from death [11, 12]. Taken together, 
our findings indicated that CPS-stimulated autophagy acts 
as a mechanism counteracting cell death and contributing 
to the survival of BC cells.
The EMT is characterized by morphological changes 
from epithelial to spindle-shaped mesenchymal like cells, 
Table 2: CPS treatment influences the Hedgehog and EMT pathways
Assay ID Gene Bank ID Symbol Description 
Fold change
5637 cell line T24 cell line
Hs03044178_g1 NM_013230 CD24 CD24 2.12 1.95
Hs01075861_m1 NM_000610 CD44 CD44 -1.49 -1.58
Hs00179843_m1 NM_000193 SHH Sonic Hedgehog -2.97 -2.24
Hs00745531_s1 NM_002181 IHH Indian Hedgehog -7.89 -2.17
Hs00368306_m1 NM_021044 DHH Desert Hedgehog 25.02 3.93
Hs00181117_m1 NM_000264 PTCH1 Patched 1 -1.72 -19.97
Hs01085642_m1 NM_001166292 PTCH2 Patched 2 2.03 7.49
Hs00977641_m1 NM_001243280 ALCAM Activated leukocyte cell adhesion molecule -2.00 -1.27
Hs00900055_m1 NM_001025366 VEGFA Vascular endothelial growth factor A 1.96 2.39
Hs00171558_m1 NM_003254 TIMP-1
TIMP 
metallopeptidase 
inhibitor 1
5.80 5.00
Hs00232783_m1 NM_001128128 ZEB1 Zinc finger E-box binding homeobox 1 -1.33 -9.85
Hs00207691_m1 NM_001171653 ZEB2 Zinc finger E-box binding homeobox 2 2.06 1.82
Custom Taqman Assay in mRNA samples extracted from untreated and CPS-treated cells for 120 h. Values represent fold 
differences of individual gene expression in CPS treated compared to untreated BC cells. The expression levels were 
normalized to the average Ct value of two housekeeping genes (GAPDH and β actin) and calculated by the ΔΔCt method. 
In bold up-regulated genes. Data shown are representative of one out of three separate experiments.
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increased cell size, loss of cell adhesion as consequence 
of changes in integrin expression, in particular α5 β1 
overexpression [15], increased invasiveness and expression 
of mesenchymal markers especially vimentin [32, 33]. CPS 
has been found to induce EMT in colon cancer cells [16], but 
no data on BC has been provided so far. To better clarify the 
effect of CPS in 5637 and T24 BC cells, we characterized 
the phenotype of CPS-resistant BC cells rescued by 
autophagy. CPS-treated BC cells show increased cell size 
and mesenchymal-like morphology, enhanced expression of 
vimentin, α5 and β1 integrin subunits and integrin like kinase 
(ILK) and anti-apoptotic Bcl-2 proteins and downregulation 
of E-cadherin. The CPS-induced EMT-positive BC cells 
are actively replicating suggesting a possible involvement 
in bladder cancer relapse. In agreement with our results, it 
is well known that ILK activation is involved in survival, 
proliferation, motility, invasion, angiogenesis [34] and that 
ILK silencing inhibits EMT, cell growth and metastasis in 
BC cells [35]. In addition in BC, increased Bcl-2 proteins, 
that correlates with high pathologic stage, disease recurrence 
and mortality rate [36], may enhance the resistance to 
necrotic death and support the BC autophagic survival.
Figure 5: The Hedgehog signaling pathway is involved in the CPS-induced autophagy and EMT phenotype. A. PTCH2 
mRNA expression, normalized to GAPDH levels, was evaluated in siGLO and siPTCH2 BC cells by qRT-PCR.*p<0.01 siPTCH2 vs siGLO 
BC cells. B. Lysates from siGLO and siPTCH2 BC cells treated for 72 h with CPS (300 μM) were separated on 14% SDS-PAGE and probed 
with anti-LC3 Ab. Cropped blots are representative of one of three separate experiments. Bars represent the densitometric analysis, shown as 
the mean ± SD of three different experiments, evaluated using siGLO cells as calibrator. *p<0.01 CPS-treated siPTCH2 vs CPS-treated siGLO 
cells. C. FACS analysis was performed in siGLO and siPTCH2 BC cells, treated with CPS (300 μM) for 120 h, stained with anti-vimentin and 
anti-α5 integrin subunit Abs followed by respective FITC-conjugated secondary Abs. One representative out of three independent experiments is 
shown. Numbers indicate the Mean Fluorescence Intensity (MFI).
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Activation of the Hedgehog pathway in human BC 
cells and its association with BC progression and clinical 
outcome have been recently reported [17, 37–39]. Herein, 
by qRT-PCR, we observed that exposure of BC cells to 
high dose of CPS for 120 h, modulates the expression of 
different members of the Hedgehog signaling pathway. 
Thus, upregulation of Dhh/Ptch2/Zeb2, as well as 
downregulation of Shh and/or Ihh/Ptch1/Zeb1 transcripts 
were found in CPS-treated BC cells, as respect to control 
cells. In addition, the silencing of PTCH2 gene in BC 
cells inhibited the CPS-induced autophagy and reverted 
the EMT phenotype, as evaluated by the reduction of 
LC3-II, vimentin and α5 integrin subunit. Hedgehog (Hh) 
signals acts as survival factor by maintaining the viability 
of UC cells and increased Hh activity is required for BC 
cell growth. Constitutive activation of different members 
(e.g. ligands and receptors) of the Hedgehog pathway 
highly correlates with BC progression [17]. Recent 
evidence in HeLa cells showed that Ptch2 overexpression, 
increased LC3-II levels and autophagy, in the absence 
and presence of BAF, and knockdown of PTCH2 reduced 
the LC3-II levels in basal and induced autophagy [40]. 
Increased PTCH2 mRNA expression correlates with 
poorer overall survival in muscle-invasive BC [37] and 
a functional link of PTCH2 in regulating the activation 
of Dhh pathway has been suggested [41]; moreover 
enhanced Dhh expression was associated with invasive 
prostate and bladder cancers and hormone-refractory 
behaviour [42]. In addition, overexpression of Zeb2, a 
transcription factor detected in infiltrating UC [43], that 
promotes the EMT [44] and regulates the expression of 
integrins [45], may be responsible for the increase of α5 
integrin expression level in EMT-positive CPS-treated 
T24 and 5637 BC cells.
Figure 6: CPS-resistant BC cells characterized by EMT phenotype, show resistance to chemotherapeutic agents. A-B. 
BC cells treated with CPS for 120 h were detached, counted and plated for additional 48 h in medium supplemented with different doses of 
mitomycin C, gemcitabine or doxorubicine. At the end of treatment MTT assays were performed. Data shown are the mean ± SE of three 
independent experiments. *p<0.01 CPS-treated vs untreated BC cells. IC50 was calculated using GraphPad.
Oncotarget50190www.impactjournals.com/oncotarget
We also found increased expression of EMT-related 
genes such as CD24, VEGFA, TIMP1 and decreased 
levels of activated cell adhesion (ALCAM/CD166) and 
CD44 molecules in BC cell lines treated with CPS. The 
CD24 and CD44 antigens mark distinct cell population 
in BC [46], and CD24 expression has been associated 
with a more aggressive phenotype, reduced survival and 
poor prognosis [47]. Metalloproteases and their inhibitors, 
TIMPs, play a pivotal role in BC progression. TIMP1 
overexpression correlates with pathological stage and 
poor prognosis in BC and induces the phenotypic changes 
linked with increased vimentin levels [48]. Furthermore, 
ALCAM loss/downregulation is associated with a more 
invasive phenotype and poorer outcome in BC [49]. Since 
the key-role of VEGFA in vimentin expression promoting 
EMT changes [50] and chemoresistance [51] in BC cells, 
VEGFA overexpression may be partially responsible for 
the acquisition of the EMT phenotype and drug resistance 
found in CPS-treated BC cells.
The EMT regulates drug-resistance and invasion 
in BC cells [36], and EMT prevention increases the 
BC sensitivity to anti-neoplastic agents [14]. The 
development of chemoresistance during BC treatment 
prejudices the effects of the chemotherapy agents and 
is responsible for the high morbidity and mortality of 
BC in the world [52]. Here, we found that CPS-induced 
EMT in BC cells results in an increased drug-resistance 
of BC cells to the cytotoxic effects of mitomycin C, 
gemcitabine and doxorubicine.
From a clinical point of view, it is now well 
established that the induction of autophagy interferes 
with the efficacy of cancer therapeutics [53]. In fact, 
recent studies reported increased chemoresistance in BC 
cells with concurrent up-regulation of autophagy related 
genes [54]. At this regard, at present, there is substantial 
evidence demonstrating the improved therapeutic effects 
by using the established cancer therapeutics agents in 
combination with autophagy inhibitors [53].
Overall, our results, showing that the escape of 
BC cells from CPS-induced death, by triggering the 
autophagic survival, Hedgehog pathway activation, 
EMT and chemotherapy drug resistance, are in line with 
these recent findings. Therefore the treatment of BC 
cells with CPS in combination with specific autophagic 
or EMT/Hedgehog pathway inhibitors, could represent 
an interesting new approach in BC therapy.
MATERIALS AND METHODS
Cell lines
5637 and T24 BC cell lines, purchased from Leibniz-
Institute DSMZ (Braunschweig, Germany) on May 5, 
2015 with authentication by DNA typing, were maintained 
in RPMI-1640 medium (Lonza Bioresearch, Basel, 
Switzerland) supplemented with 10% heat-inactivated 
fetal bovine serum, 2.5 mM N-2-hydroxyethylpiperazine-
N’-2-ethanesulfonicacid (HEPES), 2 mM L-glutamine, 
100 IU/ml of penicillin and 100 μg/ml of streptomycin 
(Lonza) at 37 °C, 5% CO2 and 95% humidity.
Reagents
Capsaicin (CPS, trans-8-methyl-N-vanillyl-6-
nonenamide) was purchased from Sigma Aldrich (MO, 
USA). The following antibodies (Abs) were used: anti-p62, 
anti-AMPK, anti-pAMPK, anti-ATG4C and anti-Beclin 
1 (1:1000, Cell Signaling Technology, CO, USA), anti-
microtubule-associated protein-1ight chain 3 (LC3, 2 μg/
ml, Novus Biologicals, CO, USA), horseradish peroxidase 
(HRP)-conjugated anti-glyceraldehyde-3-phosphate 
dehydrogenase (anti-GAPDH, 1:5000, Sigma Aldrich), 
anti-α5 integrin (1:25, Beckman Couture, FL, USA), anti-β1 
integrin (1:50, Santa Cruz Biotechnology, CA, USA), 
anti-Bcl2 (1:50, Bethyl Laboratories Inc, TX, USA), anti- 
Integrin linked kinase (ILK, 1:50, Bethyl Laboratories 
Inc), anti-vimentin (1:50, Merk Millipore, MA, USA), 
anti-E cadherin (1:50, Santa Cruz Biotechnology), anti-
BrdU (1:20, Becton Dickinson Biosciences, CA, USA). 
The following secondary Abs were used: HRP-conjugated 
donkey anti-rabbit (1:2000) and HRP-conjugated sheep 
anti-mouse (1:2000) from GE Healthcare Bio-Sciences 
(Uppsala, Sweden), FITC-conjugated anti-mouse Ab 
(1:40), FITC-conjugated anti-rabbit (1:40) and FITC-
conjugated donkey anti-goat (1:40) Abs were from Santa 
Cruz Biotechnology. 5,5,6,6-tetrachloro-1,1,3,3-tetraethyl
benzimidazolylcarbocyanine iodide (JC-1, 10 μg/ml) and 
Acridine Orange (AO 1 μg/ml) were from Invitrogen (CA, 
USA). 20,70-Dichlorofluorescein diacetate (DCFDA, 10 
μg/ml), dimethyl sulfoxide (DMSO, used as vehicle), N 
acetylcysteine (NAC, 10 mM), Diphenyleneiodonium 
chloride (DPI, 0.1 μM), Rotenone (ROT, 1 μM), 5-bromo-
2-deoxyuridine (BrdU), propidium iodide (PI, 2 μg/ml) 
and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) were from Sigma Aldrich. Bafilomycin 
A1 (BAF, 25 nM) was from Labogen (Catania, Italy). 
Annexin V-FITC (5 μl/ml) was purchased from Enzo Life 
Sciences (NY, USA).
Beclin 1 and PTCH2 gene silencing
siGENOME SMARTpools for Beclin 1 (siBeclin 
1), siCONTROL nontargeting siRNA (siGLO) used as 
negative control were purchased from Thermo Scientific-
Dharmacon (CO, USA). For gene silencing experiments, 
5637 and T24 cells were plated in a six well plate at 
the density of 3 x 104/ml and 160 pmol of siBeclin 1 or 
siGLO was added to the wells for 48 h, following the 
METAFECTENE SI PRO transfection protocol (Biontex 
Laboratories, CA, USA).
To knockdown PTCH2, the GeneSolution siRNA 
for PTCH2 (siPTCH2), negative control siRNA duplex 
(siGLO) and the HiPerfect Transfection reagent (Qiagen, 
CA, USA) were used following the Fast-forward 
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Transfection protocol. Briefly 5637 and T24 cells were 
plated in a twenty-four well plate at the density of 5 x 104/
ml and siPTCH2 or siGLO at the concentration of 5nM 
were added to the wells for 48 h. Then silenced cells were 
detached, counted and plated for MTT, western blot and 
FACS analyses.
MTT assay
The colorimetric MTT assay was used to evaluate cell 
viability. Briefly, 5637 and T24 BC cells (3x104/ml) were 
seeded into 96-well plates and cultured with CPS (300 μM) 
for 72 and 120 h at 37°C, 5% CO2. At the end of treatment, 
0.8 mg/ml of MTT was added to the samples and incubated 
for 3 h. Then the supernatants were discarded and coloured 
formazan crystals, dissolved with 100 μl/well of DMSO, 
were read by an enzyme-linked immunosorbent assay reader 
(BioTek Instruments, VT, USA). Four replicates were used 
for each treatment and data were represented as the average 
of at least three separate experiments. In some experiments, 
BC cells silenced or not for Beclin 1, were treated with CPS 
(300 μM) for 72 h before to perform the MTT assay. Finally 
to assess drug resistance, the assay was performed in BC 
cells, that after treatment with CPS for 120 h, were detached, 
counted, plated at 3x104/ml in a 96 well plate and treated for 
additional 48 h with different doses (from 0.01 to 50 μM) 
of mitomycin C, gemcitabine and doxorubicine. The half 
maximal inhibitory concentration (IC50) was determined 
using GraphPad (GraphPad Software, CA, USA).
Cell death analysis
To evaluate cell death, 5637 and T24 cells (3x104/
ml), untreated or treated for different times (24, 48 and 72 
h) with CPS (300 μM) alone or in combination with BAF 
(25 nM), were stained with PI. To assess cell death type, 
BC cells treated for 72 h with CPS alone or in combination 
with BAF were also double stained with Annexin V-FITC 
and PI. The percentage of positive cells determined over 
10000 events was analysed on a FACScan cytofluorimeter 
using the CellQuest software.
AVO detection
5637 and T24 BC cells (3x104/ml) were seeded into 
24-well plates and treated or not with CPS (300 μM) for 
48 h. Cells were then washed with medium, stained with 
AO (1μg/ml) for 15 min and analyzed on a FACScan 
cytofluorimeter using the FL1 and FL3 fluorescence. The 
percentage of positive cells determined over 10000 events 
was evaluated using the CellQuest software.
Western blot analysis
5637 and T24 cells, untreated or treated CPS (300 
μM) for different times, were lysed in a lysis-buffer 
containing protease inhibitor cocktail (Sigma Aldrich). 
Lysates were separated on sodium dodecyl sulphate 
polyacrylamide gel (9 and 14%) and transferred. After 
blocking with 5% low-fat dry milk in phosphate-buffered 
saline (PBS) 0.1% Tween 20 for l h, blots were incubated 
with the primary Abs: anti-LC3, anti-p62, anti-AMPK, 
anti-pAMPK, anti-Atg4C, or anti-GAPDH, followed by 
the appropriate HRP-conjugated antibodies. To assess 
the autophagic flux, cells were treated with CPS alone or 
in combination with BAF (25 nM). The LC3 conversion 
was also assessed in BC cells treated for 72 h with CPS 
(300 μM) alone or in combination with NAC (10 mM). In 
addition, western blot was performed in lysates from siGLO 
or siBeclin 1 BC cells, treated or not with CPS (300 μM) 
for 72 h, using anti-Beclin 1 or anti-LC3 Abs, to evaluate 
silencing efficacy and autophagy respectively. Moreover 
LC3 levels were investigated in lysates from siGLO or 
siPTCH2 BC cells treated, as above described, with CPS. 
The detection was performed using LiteAblot Turbo 
(EuroClone, Milano, Italy) and densitometric analysis was 
carried out evaluating three independent experiments by 
Chemi-Doc using Quantity One software (Bio-Rad, CA, 
USA). GAPDH levels were used as loading control.
ROS production
5637 and T24 BC cells (3x104/ml) were seeded into 
24-well plates and cultured for 4, 8, 12, 20 and 24 h with 
CPS (300 μM) or vehicle. Cells were washed with PBS, 
pulsed with DCFDA for 10 min at 37°C, 5% CO2, and 
analyzed by FACScan cytofluorimeter using the CellQuest 
software. In some experiments, ROS production was 
assessed in BC cells treated for 24 h with CPS (300 μM) 
alone or in combination with NAC (10 mM), ROT (1μM) 
and DPI (0.1 μM).
Mitochondrial transmembrane potential (ΔΨm)
ΔΨm was evaluated by JC-1 staining. 5637 and 
T24 BC cells (3x104/ml), seeded into 24-well plates, were 
treated with CPS (300 μM) or vehicle for different times 
(0, 6, 8, 12 and 24 h) and then incubated for 10 min at 
room temperature with JC-1. JC-1 was excited by an argon 
laser (488 nm); green (530 nrn)/red (>570 nrn) emission 
fluorescence was collected simultaneously. Carbonyl cyanide 
chlorophenylhydrazone protonophore, a mitochondrial 
uncoupler was used as positive control (data not shown). 
Samples were analyzed by a FACScan cytofluorimeter using 
the CellQuest software; fluorescence intensity was expressed 
in arbitrary units on logarithmic scale.
Measurement of ADP/ATP ratio
5637 and T24 BC cells (3x104/ml) were seeded into 
96-well plates and cultured with CPS (300 μM) for 12 
h at 37°C, 5% CO2. At the end of treatment, ADP/ATP 
ratio was measured by the EnzyLight ADP/ATP Ratio 
Assay Kit (BioAssay Systems, CA, USA) following the 
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instructions. Bioluminescence was acquired by FluoStar 
OMEGA luminometer (BMG LABTECH GmbH, 
Ortenberg, Germany).
Gene expression analysis
Total RNA was extracted from 5637 and T24 BC 
cells, treated for 12 h with CPS (300 μM) or vehicle, 
with the RNeasy Mini Kit (Qiagen) and reverse 
transcribed using the Reaction Ready first strand cDNA 
kit (Superarray Bioscience Corporation, MD, USA). 
Quantitative Real Time PCR (qRT–PCR) was performed 
using the IQ5 Multicolor Real-time PCR detection system 
(Bio-Rad), the RT2 real-time SYBR green PCR Mix and 
the Human Autophagy plates according to the protocol 
(Qiagen).
In addition, total RNA from BC cells, untreated or 
treated with CPS (300 μM) for 120 h, was extracted with 
the RNeasy Mini Kit (Qiagen), and cDNA was synthesized 
using the High-Capacity cDNA Archive Kit (Applied 
Biosystems, PA, USA) according to the manufacturer’s 
instructions. The EMT pathway was analysed by qRT–
PCR using a Custom Taqman assay (Thermofisher 
Scientific, MA, USA). Moreover, to evaluate the efficacy 
of PTCH2 silencing, qRT–PCR was performed using 
ddPCR GEX Assay for PTCH2 and GAPDH (Bio-Rad) 
and the QuantiFast Multiplex PCR Master Mix (Qiagen).
Fluorescence-activated cell sorting analysis
5637 and T24 BC cells, plated in 24 well plate at 
the concentration of 3x104/ml, were treated with vehicle 
or CPS (300 μM) for 120 h. Then cells were detached, 
counted and fixed with 4% paraformaldehyde for 10 min at 
room temperature. After washing in staining buffer (0.1% 
sodium azide, 1% FBS in PBS) cells were stained with 
anti-β1 and anti-α5 integrin subunits followed by FITC-
conjugated secondary Ab. In addition BC cells were also 
permeabilized using Perm solution (1% saponin, 0.1% 
sodium azide, 1% FBS in PBS) and labelled with anti-E 
cadherin, anti-vimentin, anti-ILK and anti-Bcl2 followed 
by respective FITC-conjugated secondary Abs. In some 
experiments, the expression of vimentin and α5 integrin 
subunit was valuated in siGLO and siPTCH2 cells after 
treatment for 120 h with CPS. Samples were analysed by 
a FACScan cytofluorimeter using the CellQuest software 
(Becton Dickinson).
Morphological analysis
5637 and T24 BC cells, plated in 24 well plate at the 
concentration of 3x104/ml, were treated with vehicle or 
CPS (300 μM) for 120 h. Then morphological analysis was 
assessed by citofluorimetric analysis using forward scatter 
parameter and by light microscope at X40 magnification 
using a BX51 microscope (Olympus, Milan, Italy).
BrdU incorporation
5637 and T24 BC cells, plated in 24 well plate at 
the concentration of 3x104/ml, were treated with CPS 
(300 μM) for 120 h. Then cells were detached, counted 
and plated at the concentration of 3x104/ml in a 6 well 
plate. The day after, BrdU (20 μM) was added for 
additional 24 h. At the end of the BrdU incorporation BC 
cells were fixed using 70% ice-cold ethanol and stained 
with anti BrdU Ab (1:20) followed by FITC-conjugated 
secondary Ab (1:40). Samples were analysed by a 
FACScan cytofluorimeter using the CellQuest software. 
Fluorescence intensity was expressed in arbitrary units on 
logarithmic scale.
Statistical analysis
The statistical significance was determined by 
Student’s t-test and Anova. No statistical significant 
difference was found between untreated and vehicle 
(DMSO)-treated cells or comparing different times of 
vehicle-treatment each other.
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SUMMARY
We demonstrated that capsaicin (CPS) induces 
autophagic survival in bladder cancer cells that undergo 
epithelial mesenchymal transition and acquire a more 
aggressive phenotype and drug-resistance by involving 
the Hedgehog signaling pathway.
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